Table 2 Patient characteristics for the overall group and split by RCT eligibility at baseline with those receiving an ACE inhibitor other than ramipril excluded (n = 151)
All patients (n = 3,698) | RCT(+) (n = 1,644) | RCT(−) (n = 2,054) | P-value | |
|---|---|---|---|---|
Age, years | 59.3 ± 13.0 | 57.0 ± 12.8 | 61.2 ± 12.9 | <0.0001 |
Female, % | 46.6 | 44.0 | 48.7 | <0.01 |
Body weight, kg | 83.4 ± 15.6 | 83.9 ± 15.1 | 82.9 ± 16.0 | <0.01 |
BMI, kg/m2 | 28.4 ± 4.7 | 28.3 ± 4.4 | 28.5 ± 5.0 | <0.01 |
Hypertension (HT) | ||||
Newly diagnosed HT | 37.1 | 57.2 | 21.1 | <0.0001 |
Office BP systolic, mmHg | 159.5 ± 17.1 | 162.5 ± 9.5 | 157.0 ± 21.0 | <0.0001 |
Office BP diastolic, mmHg | 93.5 ± 10.5 | 94.8 ± 8.0 | 92.5 ± 12.1 | <0.0001 |
Mean BP, mmHg | 115.5 ± 10.9 | 117.4 ± 6.7 | 114.0 ± 13.2 | <0.0001 |
Pulse pressure, mmHg | 65.9 ± 15.2 | 67.7 ± 10.9 | 64.4 ± 17.8 | <0.0001 |
BP <140/90 mmHg, % | 6.0 | 0.0 | 10.8 | <0.0001 |
Hypertension grade | ||||
High normal | 4.0 | 0.0 | 7.2 | <0.0001 |
Grade 1 | 32.2 | 25.1 | 37.9 | <0.0001 |
Any EOD* | 62.8 | 53.9 | 66.9 | <0.001 |
No EOD* | 37.2 | 46.1 | 33.1 | <0.001 |
Grade 2 | 43.4 | 60.0 | 29.8 | <0.0001 |
Grade 3 | 18.5 | 14.8 | 21.5 | <0.0001 |
Comorbidity | ||||
Diabetes, % | 19.4 | 15.3 | 22.6 | <0.0001 |
Heart failure, % | 5.7 | 3.0 | 7.9 | <0.0001 |
CAD, % | 9.6 | 5.2 | 13.2 | <0.0001 |
Prior stroke/TIA, % | 2.7 | 0.0 | 4.9 | <0.0001 |
PAD, % | 2.9 | 1.7 | 3.8 | <0.001 |
COPD, % | 7.2 | 6.4 | 7.9 | 0.09 |
Renal characteristics | ||||
Known renal disease (%) | 3.3 | 1.0 | 5.2 | <0.0001 |
Microalbuminuria, % | 6.6 | 3.4 | 9.1 | <0.0001 |